Recent Updates
Recently added Catalysts
NAUT Positive Sentiment

Investor presentation: Unlocking the power of the proteome to revolutionize biomedicine

Key Takeaway: Nautilus Biotechnology's CEO Sujal Patel and CFO Anna Mowry presented at the Q3 Investor Summit, emphasizing the need for their innovative platform to enhance drug development and precision medicine. The Nautilus Platform aims to provide comprehensive proteomic analysis with high reproducibility and sensitivity. The presentation showcased the potential of this technology to transform biomedicine.
Price reaction · baseline $0.7385 (2025-09-18T16:03:00.000Z) · hit during market hours · clean, no other NAUT news in the window
day 0 close · peak
-1.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nautilus is poised to revolutionize drug development.
  • The platform offers unmatched accuracy and sensitivity in proteomics.
  • The presentation highlights the potential for precision medicine.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
MDMA
Phase 2 · Post-Traumatic Stress Disorder

Full Press Release Details

Nautilus and our Platform
Nautilus Biotechnology
September 18, 2025
Nautilus Co-Founder and CEO Sujal Patel joined CFO Anna Mowry at the Q3 Investor Summit Group Virtual Conference to share why the world needs the Nautilus Platform to vastly improve drug development and usher in a new era of precision medicine. Watch the presentation to discover why we’re excited to redefine proteomics with a complete solution designed to confidently quantify the entire proteome and its myriad proteoforms with unbeatable reproducibility, accuracy, precision, and single-molecule sensitivity.
Watch the presentation
Share this Article
Stay up-to-date on all things Nautilus
World-class articles, delivered weekly
MORE ARTICLES
Nautilus: Driving a revolution in proteomic analysis
New protein sequencing technology from Nautilus is unlocking the proteome and igniting a proteomics revolution.
Read more
A brief introduction to PrISM – The theoretical framework underpinning the Nautilus platform
Learn about Protein Identification by Short epitope Mapping (PrISM) - The theoretical framework underpinning the Nautilus Platform.
Read more
Nautilus: Driving a revolution in proteomic analysis (Part 2)
We give you an inside view on how cross-disciplinary thinking and collaboration will propel us into a proteomics-powered future.
Read more
Stay up-to-date on all things Nautilus

Subscribe to our Newsletter

Frequently Asked Questions

What did Nautilus present at the Q3 Investor Summit?

Nautilus showcased its platform aimed at improving drug development and precision medicine.

Who represented Nautilus at the conference?

CEO Sujal Patel and CFO Anna Mowry represented Nautilus at the Q3 Investor Summit.

What is the focus of the Nautilus Platform?

The Nautilus Platform focuses on quantifying the entire proteome with high accuracy and sensitivity.

What potential does Nautilus see in its technology?

Nautilus believes its technology can revolutionize biomedicine through enhanced proteomic analysis.

Last updated: Sep 18, 2025